Improving risk prediction for fatty liver disease in people with type 2 diabetes
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes: a Cross-sectional Study
This study is trying to find out how genetics affects the risk of fatty liver disease getting worse in people with type 2 diabetes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 30 Years to 70 Years |
| Sex | All |
| Sponsor | Medanta, The Medicity, India Academic / other |
| Locations | 1 site (Gurgaon, Haryana) |
| Trial ID | NCT06289387 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the genetic factors that contribute to the risk of metabolic (dysfunction)-associated fatty liver disease (MAFLD) and its progression to cirrhosis in individuals with type 2 diabetes. By analyzing gene variants in a population of Indian individuals aged 30 to 70, the study seeks to identify why only a small percentage of those with MAFLD develop severe liver disease. The findings could help in understanding the complex interplay of genetics and environmental factors in the disease's progression. The study is conducted at Medanta, The Medicity in Gurgaon, Haryana.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 30 to 70 years, with or without type 2 diabetes.
Not a fit: Patients under 30 years old or those with significant alcohol intake or viral hepatitis infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved risk assessment and personalized management strategies for patients with type 2 diabetes and fatty liver disease.
How similar studies have performed: Other studies have shown success in identifying genetic factors related to liver disease, but this specific approach focusing on the Indian population is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Individuals with or without T2DM between ages 30 to 70 years Exclusion Criteria: Age below 30 years Patients with hepatitis B, hepatitis C or HIV disease Patients with significant alcohol intake (\>14 drinks/week in men and \>10 drinks/week in women). Patients on corticosteroids and chemotherapeutic agents.
Where this trial is running
Gurgaon, Haryana
- Medanta Division of Endocrinology & Diabetes — Gurgaon, Haryana, India (Recruiting)
Study contacts
- Study coordinator: Mr Surender, PhD
- Email: yadavsurender89@gmail.com
- Phone: 01244141414
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.